MedTrace Logo

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

NCT01216267 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-01-16

No results posted yet for this study

Summary

The goal of this study is to compare several methods for measurement of Chromogranin A in their ability to serve as a marker for disease activity in patients with neuroendocrine tumors.

Further, in a subgroup, we will determine if taking a proton pump inhibitor affects Chromogranin A levels.

Conditions

  • Neuroendocrine Carcinoma (Carcinoid)

Interventions

DRUG

Lansoprazole

lansoprazole 30 mg HS x 7 days

DRUG

lansoprazole

lanzoprazole 30 mg HS for 7 days

Sponsors & Collaborators

  • University of Western Ontario, Canada

    lead OTHER

Principal Investigators

  • Stan Van Uum, MD PhD · Western University, Canada

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01216267 on ClinicalTrials.gov